Jump to ContentJump to Main Navigation
Comparative Effectiveness ResearchEvidence, Medicine, and Policy$
Users without a subscription are not able to see the full content.

Carol M. Ashton and Nelda P. Wray

Print publication date: 2013

Print ISBN-13: 9780199968565

Published to Oxford Scholarship Online: September 2013

DOI: 10.1093/acprof:oso/9780199968565.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in OSO for personal use. date: 16 December 2019

The Legislative Odyssey of Comparative Effectiveness Research

The Legislative Odyssey of Comparative Effectiveness Research

Birth in 2002 to the First Federal Mandate in 2003

(p.135) 7 The Legislative Odyssey of Comparative Effectiveness Research
Comparative Effectiveness Research

Carol M. Ashton

Nelda P. Wray

Oxford University Press

From a nearly imperceptible start, federal policy on comparative effectiveness research gained substantial momentum over its eight-year odyssey and got several legislative toeholds. The story starts in May 2002 with a short bill introduced into the US House of Representatives by Representative Thomas Allen (D-Maine). This bill focused solely on prescription drugs and would have authorized the appropriation of $25 million for comparative effectiveness research to the Agency for Healthcare Research and Quality. It died in committee. The next year Representative Allen and a Republican co-sponsor JoAnn Emerson (R-Missouri) introduced a more ambitious bill that encompassed all treatments, not just drugs. By means of a circuitous path involving Senate Majority Leader Bill Frist (R-Tennessee) many elements of the 2003 Allen-Emerson bill became law as part of the 2003 Medicare Modernization Act passed by the Republican-held Congress and signed by Republican President George W. Bush.

Keywords:   U.S. Representative Thomas Allen (D-ME), Prescription Drug Comparative Effectiveness Act of 2003 (H.R. 2356), Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (P.L. 108-173), Senator Hillary Clinton (D-NY), Senate Majority Leader Bill Frist (R-TN), Agency for Healthcare Research and Quality

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .